Media headlines about Otonomy (NASDAQ:OTIC) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Otonomy earned a daily sentiment score of 0.08 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.0152697090641 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Otonomy (NASDAQ OTIC) traded up $0.17 during trading on Tuesday, hitting $5.85. The company’s stock had a trading volume of 309,300 shares, compared to its average volume of 326,136. The company has a market cap of $172.16, a price-to-earnings ratio of -1.81 and a beta of 3.33. Otonomy has a twelve month low of $2.80 and a twelve month high of $21.15.

Otonomy (NASDAQ:OTIC) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.69) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.84) by $0.15. The business had revenue of $0.28 million during the quarter, compared to analyst estimates of $0.43 million. Otonomy had a negative return on equity of 60.74% and a negative net margin of 7,899.03%. The company’s revenue was down 12.8% on a year-over-year basis. research analysts predict that Otonomy will post -2.88 earnings per share for the current year.

A number of brokerages have issued reports on OTIC. Zacks Investment Research cut Otonomy from a “hold” rating to a “sell” rating in a research note on Wednesday, January 17th. Piper Jaffray Companies reissued a “hold” rating and issued a $8.00 target price on shares of Otonomy in a report on Friday, November 10th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $9.15.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Otonomy (OTIC) Share Price” was reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at

About Otonomy

Otonomy, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company’s product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase.

Insider Buying and Selling by Quarter for Otonomy (NASDAQ:OTIC)

Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with's FREE daily email newsletter.